Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference7 articles.
1. Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
2. Uptake of new heart failure drug slow, say makers.
http://www.cardiomyopathy.org/news%2D%2Dmedia/latest-news/post/126-uptake-of-new-heart-failure-drug-slow-say-makers
. Updated November 6, 2015. Accessed 18 Oct, 2017.
3. Packer M. Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. Eur J Heart Fail. 2016;18:1211–9.
4. Packer M, Armstrong WM, Rothstein JM, Emmett M. Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med. 2016;165:735–6.
5. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–8.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献